Ralf Pasternack Zedira managing partner
Ralf Pasternack was born on November 4th, 1967 in Wiesbaden, Germany.
He studied Chemistry at the Technical University Darmstadt and received his Diploma in Biochemistry in 1994 working in the group of Prof. H.G. Gassen. In 1998 he obtained his PhD working on Microbial Transglutaminase from Streptomyces together with Prof. H.-L. Fuchsbauer & Prof. H.G. Gassen.
Together with both supervisors and Dr. Jochen Klein (former CEO of the Doehler Group) he founded his first core Biotech company called N-Zyme BioTec and served as CEO. In 2007 he co-founded Zedira by a management buyout and holds the function of a CEO. The company specializes on therapeutic and diagnostic applications of transglutaminase.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • Life Sciences 2019: Post-translational modifications and cell signalling

    17.03.2019 - 18.03.2019
    Nottingham, UK

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France